S2 File - Factors influencing effective decrease of controlled attenuation parameters in metabolic-associated steatotic liver disease: A multilevel linear regression analysis at Va... by Sonsawan Sangprasert (22772538)

Larger example of stimuli with cue relevant for Task 3. by Marcel F. Hinss (14675457)

Subjects:

The results of linear mixed model. by Soheila Qanbari (20455173)

Subjects:

Rates of change in each retinal layer thickness, calculated using linear mixed models. by Jung-Tae Kim (8997767)

Subjects:

Linear mixed-effect model determination of factors associated with changes in best-corrected visual acuity. by Jung-Tae Kim (8997767)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Study CONSORT diagram. by Benjamin R. Lewis (22279166)

Subjects:

STL Linear Combination Forecast Graph. by Xiangjuan Liu (618000)

“…Further integration of Spearman correlation analysis and PCA dimensionality reduction created multidimensional feature sets, revealing substantial accuracy improvements: The BiLSTM model achieved an 83.6% cumulative MAE reduction from 1.65 (raw data) to 0.27 (STL-PCA), while traditional models like Prophet showed an 82.2% MAE decrease after feature engineering optimization. …”

Linear relationships (Spearman’s r (p-value)) the treatment-induced changes in clinical and neurophysiological data. by Soheila Qanbari (20455173)

Subjects:

The linearly decreasing convergence factor a. by Junhao Wei (6816803)

Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

Statistically significant linear increase in use of antidepressants during the observed time period. by Jelena Filimonovic (22305307)

Multiple linear regression analysis for psychological distress (GHQ-12 scores). by Kazuhiro Suzuki (160528)

Subjects:

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects: